Market Overview:
The global epidermal growth factor receptor inhibitor market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The market is segmented on the basis of type, application and region. On the basis of type, the market is segmented into lung cancer, colorectal cancer, breast cancer and others. Colorectal cancer held a dominant share in 2017 and it is expected to maintain its dominance during the forecast period as well. On the basis of application, hospital held a dominant share in 2017 and it is expected to maintain its dominance during the forecast period as well. However, research institutes are projected to witness highest growth rate owing to increasing R&D expenditure by pharmaceutical companies for development of novel EGFR inhibitors.
 Inhibitor Industry Outlook.svg)
Product Definition:
An epidermal growth factor receptor (EGFR) inhibitor is a molecule that blocks the activation of EGFR, thereby inhibiting tumor cell growth. EGFR inhibitors are used to treat cancers that have high levels of EGFR activity, such as non-small cell lung cancer and pancreatic cancer.
Lung Cancer:
Lung cancer is a type of cancer that begins in the lung tissues and bronchus. The most common types of lung cancers are non-small cell lung carcinoma (NSCLC) and small cell lung carcinoma (SCLC). Lung cancer has different forms which include small-cell, non-small cell, adenocarcinoma, squamous cell carcinoma & other less common types.
Colorectal Cancer:
Colorectal cancer (CRC) is one of the most common cancers occurring in the world. According to American Cancer Society, it accounted for nearly 23.0% of all cancers in 2012 and is expected to be among the top three causes of deaths worldwide by 2030.
Application Insights:
The other application segment includes cutaneous cancer, head and neck cancer, and others. The EGFR inhibitors are FDA approved for the treatment of colorectal cancer, lung cancer, breast cancer (in postmenopausal women), and others. Currently available drugs in the market are indicated for the treatment of EGFR-positive non-small cell lung cancers that have a history of exposure to radiation or chemotherapy as well as patients with metastatic breast carcinoma.
The hospital application segment is expected to witness lucrative growth over the forecast period owing to increasing awareness about advanced treatments such as surgery followed by radiotherapy in order to cure various types of cancers including skin ones. According to data published by NCBI in 2018 regarding survival rates after different types of surgeries performed on people diagnosed with malignant tumors all over the world; it can be seen that surgical procedures like mastectomy followed by radiotherapy have better outcomes than those performed via conventional methods alone such as surgery only.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of major players, high adoption rate of new technologies, and availability of advanced products for treatment options. Moreover, favorable reimbursement policies are also expected to drive growth during the forecast period. Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to rising disposable income levels and increasing healthcare spending by governments & private sectors in countries such as China & India.
Key Companies Mentioned In The Report Include Merck KGaA; Pfizer Inc.; Celgene Corporation; Bristol-Myers Squibb Company; AbbVie Inc.
Growth Factors:
- Increasing incidence of cancer: The increasing incidence of cancer is the major growth driver for the epidermal growth factor receptor inhibitor market. According to the American Cancer Society, in 2016, around 1,685,210 new cases of cancer will be diagnosed in the U.S., and approximately 595,690 people will die from this disease. This number is expected to rise in future due to increase in aging population and unhealthy lifestyle habits such as smoking and alcohol consumption.
- Rising demand for targeted therapies: The rising demand for targeted therapies is another key growth driver for the epidermal growth factor receptor inhibitor market. Due to their specificity towards certain types of tumors, these drugs are increasingly being preferred over traditional chemotherapy regimens that are less specific and cause more side effects.
- Technological advancements: The advent of novel technologies such as next-generation sequencing (NGS) has led to a better understanding of tumor biology which is aiding the development of better targeted therapies like EGFR inhibitors . This technological advancement is helping fuel the growth of this market segment .
Scope Of The Report
Report Attributes
Report Details
Report Title
Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Research Report
By Type
Lung Cancer, Colorectal Cancer, Breast Cancer, Others
By Application
Hospital, Research Institutes and Research Institutions, Clinic, Other
By Companies
Amgen Inc., AstraZeneca Plc, Eli Lilly and Co., F. Hoffmann-La Roche Ltd., Novartis AG
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
190
Number of Tables & Figures
133
Customization Available
Yes, the report can be customized as per your need.
Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Report Segments:
The global Epidermal Growth Factor Receptor (EGFR) Inhibitor market is segmented on the basis of:
Types
Lung Cancer, Colorectal Cancer, Breast Cancer, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Research Institutes and Research Institutions, Clinic, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Amgen Inc.
- AstraZeneca Plc
- Eli Lilly and Co.
- F. Hoffmann-La Roche Ltd.
- Novartis AG
 Inhibitor Market Overview.svg)
Highlights of The Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Lung Cancer
- Colorectal Cancer
- Breast Cancer
- Others
- By Application:
- Hospital
- Research Institutes and Research Institutions
- Clinic
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Epidermal Growth Factor Receptor (EGFR) Inhibitor Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Inhibitor Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Epidermal growth factor receptor (EGFR) inhibitors are medications that block the activity of EGFR. This can slow or stop the growth of cancer cells.
Some of the key players operating in the epidermal growth factor receptor (egfr) inhibitor market are Amgen Inc., AstraZeneca Plc, Eli Lilly and Co., F. Hoffmann-La Roche Ltd., Novartis AG.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Epidermal Growth Factor Receptor (EGFR) Inhibitor Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Epidermal Growth Factor Receptor (EGFR) Inhibitor Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Size & Forecast, 2018-2028
4.5.1 Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Size and Y-o-Y Growth
4.5.2 Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Absolute $ Opportunity
Chapter 5 Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Size Forecast by Type
5.2.1 Lung Cancer
5.2.2 Colorectal Cancer
5.2.3 Breast Cancer
5.2.4 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Research Institutes and Research Institutions
6.2.3 Clinic
6.2.4 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Epidermal Growth Factor Receptor (EGFR) Inhibitor Analysis and Forecast
9.1 Introduction
9.2 North America Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Size Forecast by Type
9.6.1 Lung Cancer
9.6.2 Colorectal Cancer
9.6.3 Breast Cancer
9.6.4 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Research Institutes and Research Institutions
9.10.3 Clinic
9.10.4 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Epidermal Growth Factor Receptor (EGFR) Inhibitor Analysis and Forecast
10.1 Introduction
10.2 Europe Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Size Forecast by Type
10.6.1 Lung Cancer
10.6.2 Colorectal Cancer
10.6.3 Breast Cancer
10.6.4 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Research Institutes and Research Institutions
10.10.3 Clinic
10.10.4 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Epidermal Growth Factor Receptor (EGFR) Inhibitor Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Size Forecast by Type
11.6.1 Lung Cancer
11.6.2 Colorectal Cancer
11.6.3 Breast Cancer
11.6.4 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Research Institutes and Research Institutions
11.10.3 Clinic
11.10.4 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Epidermal Growth Factor Receptor (EGFR) Inhibitor Analysis and Forecast
12.1 Introduction
12.2 Latin America Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Size Forecast by Type
12.6.1 Lung Cancer
12.6.2 Colorectal Cancer
12.6.3 Breast Cancer
12.6.4 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Research Institutes and Research Institutions
12.10.3 Clinic
12.10.4 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Epidermal Growth Factor Receptor (EGFR) Inhibitor Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Size Forecast by Type
13.6.1 Lung Cancer
13.6.2 Colorectal Cancer
13.6.3 Breast Cancer
13.6.4 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Research Institutes and Research Institutions
13.10.3 Clinic
13.10.4 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Epidermal Growth Factor Receptor (EGFR) Inhibitor Market: Competitive Dashboard
14.2 Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Amgen Inc.
14.3.2 AstraZeneca Plc
14.3.3 Eli Lilly and Co.
14.3.4 F. Hoffmann-La Roche Ltd.
14.3.5 Novartis AG
